Thursday, Bionomics Limited (NASDAQ:BNOX) released a full dataset analysis from its Phase 2b ATTUNE trial of BNC210 in patients with post-traumatic stress disorder (PTSD).
In September 2023, Bionomics reported the topline results for the Phase 2b ATTUNE trial of BNC210 for PTSD, demonstrating that the trial met its primary endpoint and several secondary endpoints and that BNC210 was generally well tolerated.
The primary endpoint of mean change from baseline in the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity score was met, showing that BNC210 led to a statistically significant improvement vs placebo (p<0.05) at Week 12 with an effect size of 0.40.
The improvement in CAPS-5 ...